Among patients aged 65 years or older with type 2 diabetes, DPP-4 inhibitors were associated with a lower mortality rate, fewer MACE, and no increase in HF or hypoglycemia, which supports the concept that elderly individuals benefit from DPP-4 inhibitors (Shih et al., 2016). This evidence concerns the gene DPP4 and hydrops fetalis.